Recent reports indicated that accumulation of MDSCs may be crucial in CTCL progression (47), and Geskin et al. observed a reduction in MDSC activity following IFNα2b therapy (48), suggesting a possible correlation with the effective treatment by IFN. This evidence concerns the gene IFNA2 and primary cutaneous T-cell non-Hodgkin lymphoma.